Even without immunorejection, autologous myoblast transfer is limited by massive early cell death and poor spatial spread, making it a suboptimal vector for dystrophin gene replacement in Duchenne muscular dystrophy.
No takes yet. Share an insight, caveat, or question.
Early myoblast death limits gene delivery efficacy in dystrophic models; leaves open whether survival-enhancing strategies can advance DMD gene therapy.
Huard et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: